Waters CORP /DE/ Form 4 insider transactions

Waters Corporation and Becton, Dickinson and Company announced a proposed business combination between Waters and BD's Augusta SpinCo Corporation, aiming to double Waters' addressable market to $40 billion and enhance financial outlook.

Waters Corporation announced a definitive agreement to acquire BD's Biosciences & Diagnostic Solutions business for approximately $17.5 billion through a Reverse Morris Trust, creating a combined entity with an expanded market presence and enhanced financial profile.

Waters Corporation has filed a Rule 425 communication with the SEC, disclosing public advertisements related to its proposed business combination with Augusta SpinCo Corporation, a wholly owned subsidiary of Becton, Dickinson and Company.

Waters Corporation announces its planned acquisition of Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business, aiming to diversify revenue and accelerate expansion into bioseparations, bioanalytical characterization, and multiplex diagnostics.

Waters Corporation has filed a communication with the SEC regarding its proposed business combination with Augusta SpinCo Corporation, a wholly owned subsidiary of Becton, Dickinson and Company, outlining the transaction and associated regulatory disclosures.

Waters Corporation and Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, Augusta SpinCo Corporation, will combine to form a new life science and diagnostics leader, doubling the addressable market to $40 billion and enhancing financial outlook.

Waters Corporation and Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business are combining in a $17.5 billion Reverse Morris Trust transaction, aiming to create a diversified life science and diagnostics leader with significant synergy potential and expanded market reach.

Waters Corporation and Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business have entered into a definitive agreement for a tax-efficient Reverse Morris Trust transaction, aiming to create a diversified life science and diagnostics leader.

Waters Corporation announced a definitive agreement to combine with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business, aiming to create a leading life science and diagnostics company focused on regulated, high-volume testing.

Waters Corporation and Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business will combine to create a new life science and diagnostics leader focused on regulated, high-volume testing.

Waters Corporation and Becton, Dickinson and Company have entered into definitive agreements for a Reverse Morris Trust transaction, where BD will spin off its Biosciences and Diagnostic Solutions business (SpinCo) which will then merge with a Waters subsidiary, resulting in Waters shareholders owning approximately 60.8% and former SpinCo shareholders owning approximately 39.2% of the combined entity.

Waters Corporation and Becton, Dickinson and Company announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a $17.5 billion Reverse Morris Trust transaction, forming an innovative life science and diagnostics leader.

Waters Corporation and Becton, Dickinson & Company's Biosciences & Diagnostic Solutions business will combine in a $17.5 billion Reverse Morris Trust transaction, aiming to create a leading life science and diagnostics company with significant market expansion and synergy potential.

Waters Corp Director Heather Knight acquired 68.35 common stock units as part of her director fees, convertible into shares on January 1, 2027.

Waters Corp Director Wei Jiang acquired 68.35 common stock units as deferred compensation, aligning interests with shareholders.

Robert L. Carpio III, SVP of Waters Division at Waters Corporation, had 134 shares of common stock withheld by the company to cover tax obligations related to vested restricted stock units.

Amol Chaubal, SVP & CFO of Waters Corp, reports the withholding of shares for tax obligations and correction of a previous omission regarding shares acquired through the Employee Stock Purchase Plan.

Jianqing Bennett, SVP at Waters Corp, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Director Wei Jiang acquired common stock units in Waters Corp in lieu of cash payment for director fees, according to a Form 4 filing.

Director Heather Knight acquired Waters Corp common stock units in lieu of cash payment for director fees, convertible to shares in 2027.

Jianqing Bennett, SVP at Waters Corp, disposed of 786 shares of common stock on March 1, 2025, to cover tax withholding obligations related to vesting performance stock units.

Amol Chaubal, SVP & Chief Financial Officer of Waters Corp, disposed of shares to cover tax obligations related to vesting performance stock units.

Waters Corp CEO Udit Batra disposed of 4,976 shares of common stock on March 1, 2025, to cover tax obligations related to vesting performance stock units.

Udit Batra, President and CEO of Waters Corp, reports acquisition of common stock and stock options, including performance shares and restricted stock units, in a recent SEC Form 4 filing.

Amol Chaubal, SVP & CFO of Waters Corp, reports the acquisition of common stock and stock options, including earned performance shares and restricted stock, according to a Form 4 filing.

Waters Corp SVP Jianqing Bennett reports the acquisition of performance shares and restricted stock, along with the granting of stock options.

Robert L. Carpio III, SVP of Waters Division at Waters Corp, reports the acquisition of restricted stock units and stock options, along with an adjustment to previously reported holdings.

Director Heather Knight of Waters Corp acquired 319 shares of restricted stock and 818 stock options on January 2, 2025.

Director Wei Jiang of Waters Corp acquired 319 shares of restricted stock and 818 stock options on January 2, 2025.

Director Pearl S. Huang of Waters Corp acquired 319 shares of restricted stock and 818 stock options on January 2, 2025.